NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana G. Abramson, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Bethany Anderson, Janet E. Bailey, Harold J. Burstein, Nan Chen, Helen K. Chew, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn Leitch, Janice A. Lyons, Susie McCloskey, Melissa McShane, Joanne Mortimer, Sameer A. Patel, Laura H. Rosenberger, Hope S. Rugo, Cesar A. Santa‐Maria, Bryan P. Schneider, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Amulya Yellala, Kay T. Yeung, Jessica Young, Ryan Schonfeld, Rashmi Kumar
Abstract
The treatment landscape of invasive early-stage and metastatic breast cancer is evolving constantly. These NCCN Guidelines Insights focus on recent updates included in the most recent version (version 5.2025) of the NCCN Guidelines for Breast Cancer specific to workup, locoregional therapy, surveillance, and systemic neoadjuvant/adjuvant therapy recommendations for invasive, nonmetastatic breast cancer.